Case Series in Pakistan Reveals Rare Case of Thromboembolism Linked to Pfizer-BioNTech BNT162b2 mRNA Vaccine

138

1 comment

Staff at TrialSite | Quality Journalism

Jul. 16, 2024, 3:00 p.m.

Clinical investigators from Pakistan and Saudi Arabia led by Safi Ur Rehman Daim, M.D. Mayo Hospital Lahore and colleagues report on a case series involving an uncommon severe adverse effect such as thromboembolism, identified during post marketing surveillance COVID-19 vaccines, linked to the Pfizer BNT162b2 mRNA COVID-19 vaccine.

This recent case series published in Radiology Case Reports reveals the plight of the patient, a 26-year-old female who developed extensive pulmonary embolism following administration of the Pfizer- BNT162b2 mRNA COVID-19 vaccine.

Quality journalism costs money to produce.

Free access provides up to 10 articles

Subscription options start at $5 per month
which is less than a Starbucks coffee!

Peter Gabriel, MD

"Publishing on TrialSite helped me secure a $20m research grant for my work."

Jona Savinda

"TrialSiteNews is my daily read for what is happening in the industry."